The novel antifibrotic agent pirfenidone attenuates the profibrotic environment generated by calcineurin inhibitors in the rat salt-depletion model

被引:15
作者
Brook, NR [1 ]
Waller, JR [1 ]
Bicknell, GR [1 ]
Nicholson, ML [1 ]
机构
[1] Univ Leicester, Transplant Surg Grp, Leicester LE5 4PW, Leics, England
关键词
D O I
10.1016/j.transproceed.2004.12.150
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Calcineurin inhibitors (CNIs) promote fibrosis in renal allografts by altering the dynamics of extracellular matrix (ECM) turnover. Graft structure is changed and functional disturbance may follow. This study examined the effects of an antifibrotic agent, pirfenidone, on functional, structural, and molecular markers of fibrosis in a rat model. Cyclosporine or tacrolimus were administered to salt-depleted rats, with or without varying doses of pirfenidone. Both CNIs increased serum creatinine, and pirfenidone attenuated this functional disturbance. No changes in urinary protein excretion or graft histology were observed, suggesting structural and functional alterations can be dissociated. Messenger RNA expression of pro- and antifibrotic genes affecting ECM was estimated with semiquantitative RT-PCR. Cyclosporine-induced increases in collagen III mRNA expression were attenuated by pirfenidone (500 mg/kg/d), and increases in TIMP-1 expression were reversed by all doses of pirfenidone. Matrix metalloproteinase-2 expression was decreased by cyclosporine; all doses of pirfenidone significantly reversed this effect. Tacrolimus alone decreased TGF-beta and TIMP-1 expression, suggesting some antifibrotic action; addition of pirfenidone had no further effect. The mechanism of action of pirfenidone is reversal of some CNI-induced changes in fibrotic gene expression. It also attenuates creatinine rise in salt-depleted rats in this model of CNI-induced nephrotoxicity.
引用
收藏
页码:130 / 133
页数:4
相关论文
共 7 条
  • [1] BENNETT WM, 1994, NEPHROL DIAL TRANSPL, V9, P141
  • [2] Reproducibility in the quantification of mRNA levels by RT-PCR-ELISA and RT competitive-PCR-ELISA
    Hall, LL
    Bicknell, GR
    Primrose, L
    Pringle, JH
    Shaw, JA
    Furness, PN
    [J]. BIOTECHNIQUES, 1998, 24 (04) : 652 - +
  • [3] Iyer SN, 1999, J PHARMACOL EXP THER, V291, P367
  • [4] Tacrolimus has less fibrogenic potential than cyclosporin A in a model of renal ischaemia-reperfusion injury
    Jain, S
    Bicknell, GR
    Nicholson, ML
    [J]. BRITISH JOURNAL OF SURGERY, 2000, 87 (11) : 1563 - 1568
  • [5] Lasky J, 2004, IDRUGS, V7, P166
  • [6] THE HISTOPATHOLOGICAL CHANGES ASSOCIATED WITH ALLOGRAFT-REJECTION AND DRUG TOXICITY IN RENAL-TRANSPLANT RECIPIENTS MAINTAINED ON FK506 - CLINICAL-SIGNIFICANCE AND COMPARISON WITH CYCLOSPORINE
    RANDHAWA, PS
    SHAPIRO, R
    JORDAN, ML
    STARZL, TE
    DEMETRIS, AJ
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1993, 17 (01) : 60 - 68
  • [7] Pirfenidone inhibits early myointimal proliferation but has no effect on late lesion size in rats
    Waller, JR
    Murphy, GJ
    Bicknell, GR
    Sandford, R
    Margolin, SB
    Nicholson, ML
    [J]. EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2002, 23 (03) : 234 - 240